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Abstract: The recent development of new devices that are significantly less invasive, collectively 
termed minimally invasive glaucoma surgery, offers new perspective of intraocular pressure 
reduction with less risk, short operating times, and rapid recovery. The aim of this work is to 
provide a panoramic review of the currently published clinical data to assess the potential role 
of XEN gel stent (Allergan PLC, Irvine, CA, USA) in the management of glaucoma, which is 
the only filtering minimally invasive glaucoma surgery device that allows the subconjunctival 
filtration. The ab interno placement of the XEN gel stent offers an alternative for lowering 
intraocular pressure in refractory glaucoma as a final step, and in patients intolerant to medical 
therapy as an early surgical approach with minimum conjunctival tissue disruption, restricted 
flow to avoid hypotony, and long-term safety.
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Introduction
Glaucoma, which affects 64,300,000 people, 3.5% of the world’s population,1 is a 
heterogeneous group of optic neuropathies, which causes irreversible but potentially 
preventable vision loss, related in most form, of glaucoma to elevated intraocular 
pressure (IOP). In the healthy eye, aqueous humor (AH) flow against resistance gen-
erates an average IOP of ~15 mmHg, necessary to inflate the eye and maintain the 
proper shape and optical properties of the globe. There is an equilibrium between 
the production and drainage of AH, and impairment in outflow leads to IOP eleva-
tion. This basic concept is a central tenet of glaucoma pathology and treatment. 
Therefore, understanding AH dynamics and mechanisms is the challenge in the 
management of glaucoma. Lowering IOP through use of medication, laser treat-
ments, or incisional surgery is currently the only means of preventing progression 
of glaucoma.2
While many patients may be controlled by medications, poor compliance to 
therapy and ocular toxicity are issues that lead to an early surgical approach. The 
4 main approaches of IOP reduction include increasing trabecular outflow by bypass-
ing juxtacanalicular trabecular meshwork (TM), increasing uveoscleral outflow via 
suprachoroidal pathways, reducing AH production from the ciliary body, or creating 
a subconjunctival drainage pathway from the anterior chamber (AC).3
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Subconjunctival drainage of AH, resulting in bleb forma-
tion, has been a cornerstone of glaucoma surgery for more 
than a century4 and the superiority of external filtration 
surgery is unquestionable.
From the subconjunctival space, the AH has numerous 
potential drainage pathways, including diffusion through the 
conjunctiva, diffusion into the venous system of the sclera 
and conjunctiva, as well as potential lymphatic pathways;5,6 
furthermore, subconjunctival drainage, bypassing the TM, 
Schlemm’s canal, and collector channels entirely, eliminates 
the risk of reducing the efficacy due to any other outflow 
obstruction. All other bleb-less drainage spaces (Schlemm’s 
canal and suprachoroidal pathways) have a limitation since 
AH outflow critically depends on the venous system.7
The recent development of new devices that are significantly 
less invasive, collectively termed minimally invasive glau-
coma surgery (MIGS), offers new perspective of IOP reduction 
with less risk, short operating times, and rapid recovery.
MIGS has been defined as any glaucoma surgical proce-
dure that avoids conjunctival dissection and thus approaches 
via ab interno incision (clear cornea wound), aiming to pro-
vide a safer and less invasive means of lowering IOP than 
traditional surgery, with the goal of reducing dependency on 
topical medication.3,8
Proven outflow mechanism of action in the subconjunctival 
space with a minimally invasive approach is an important goal; 
XEN gel stent (Allergan PLC, Irvine, CA, USA) is the only 
filtering MIGS device that allows subconjunctival filtration.
The ab interno placement of the XEN gel stent offers an 
alternative for lowering IOP with minimum conjunctival 
tissue disruption, restricted flow to avoid hypotony, and 
long-term safety.
The aim of this paper is to provide a review of the cur-
rently published clinical data to assess the potential role of 
XEN gel stent in the management of glaucoma.
XeN gel stent
XEN gel stent is a hydrophilic tube made of a porcine gelatin 
cross-linked with glutaraldehyde to achieve permanence in 
tissue. This material is used for a variety of medical applica-
tions because of its well-established biocompatibility, and it 
does not cause a foreign-body reaction.9 (Figure 1A).
The implant is hard when dry and becomes soft within 
1–2 min when hydrated, adapting to the tissue shape, thus 
avoiding migration and potential erosion. It has been dem-
onstrated that the gel stent is ~100 times more flexible than 
the silicon tubing used in traditional tube–shunt surgery.4 
The implant is housed in a disposable preloaded handheld 
inserter designed specifically for an ab interno surgical 
implantation (Figure 1B).
It decreases IOP by creating a permanent outflow pathway 
from the AC to the subconjunctival space through a scleral 
channel of 2–4 mm. The first implants proposed by Aquesys 
Inc. (Aliso Viejo, CA, USA) were of 3 different diameters 
(45, 63, and 140 µm) for varying levels of IOP control.
The smallest one, XEN45, the only one currently avail-
able, has an inside diameter of ~45 µm, an outside diameter 
of 150 µm, and is 6 mm long.
It was designed from principles of laminar fluid dynam-
ics (Hagen–Poiseuille equation) to avoid early postoperative 
hypotony as demonstrated by recent experimental study.10 
Indeed, the rate of AH turnover is estimated to be 1.0%–1.5% of 
the AC volume per min, which is 2.4±0.6 µL/min (mean ± SD, 
daytime measurements in adults aged 20–83 years)11 and the 
XEN45 gives a flow of 1.2 µL/min (at 5 mmHg pressure 
gradient), providing ~6–8 mmHg flow resistance, which 
reduces the risk of hypotony.4
Surgical technique
Lewis first described the surgical procedure,4 which was 
revised further by other authors. The procedure can be 
Figure 1 (A) XeN gel stent; (B) preloaded injector and correct handling.
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performed under local or topical anesthesia. Mitomycin C 
(MMC) is generally used in a concentration of 0.1–0.2 mg/mL 
(absolute dose of 10–20 µg). It is injected with a 30-gauge 
needle in the subconjunctival supero-temporal quadrant 
space to obtain a bubble that is gently rolled toward the 
supero-nasal quadrant. This induces a hydroexpansion, which 
reduces tissue resistance, preparing the space for the implant 
and supporting the bleb formation (Figure 2). Blood vessels 
should be avoided during the introduction of the needle into 
the subconjunctival space as bleeding may compromise vis-
ibility required for the stent implantation.
Cataract surgery, if planned, may be performed after this 
step using miotic drugs after intraocular lens (IOL) implanta-
tion and ophthalmic viscosurgical device (OVD) removal. 
The intended area of placement in the supero-nasal quadrant, 
which is 3 mm from the limbus, is marked. The AC is filled 
with standard cohesive OVD and an infero-temporal 1.8 mm 
clear corneal incision is created through which the preloaded 
inserter needle (double-beveled 27 gauge) is directed across 
the AC to the opposite side to penetrate the angle. The needle 
passes through the sclera and emerges in the subconjunctival 
space ~3.0 mm posterior to the limbus, as previously marked, 
in the target supero-nasal quadrant. Once the tip of the needle 
is visible in the subconjunctival space, it is rotated toward 
the 12 o’clock position and the stent is gently delivered by 
advancing the sliderat.
The needle housing the implant is retracted without draw-
ing the implant back. During this step, to stabilize the eye, 
a straight micro-manipulator is used in the side port corneal 
incision to maintain contact between the needle sleeve and 
the angle. (Figure 3) De Gregorio et al described a “three 
hands technique” in which the sliderat is pushed by a third 
hand; this allows reduction of the inserter movements, sta-
bilizing the contact during stent delivery.12 The ideal stent 
placement should leave 2.0 mm of exposed implant in the 
subconjunctival space (preferentially in a more superficial 
layer than the sub-Tenon space), 1.0 mm in the AC, and 
3.0 mm tunneled through sclera (Figure 4).
The use of a mirrored gonioscope to verify placement 
through the angle and avoid iris root trauma is not always 
necessary, and is used at the discretion of the surgeon. The 
OVD is then washed, allowing the implant, when correctly 
positioned and patent, to immediately begin shunting fluid 
from the AC to the subconjunctival space. The initial bleb 
extends further into the non-dissected conjunctiva due to a 
gentle diffusion of the AH.
Better bleb morphology and function may be obtained by 
forced infusion of the fluid through paracentesis at the end of the 
procedure. All corneal incisions are sutured or hydro-sutured.
Antibiotic drug prophylaxis of the surgeon’s choice is 
generally continued for the first 2 weeks and it is associated 
with a topical corticosteroid 4 times each day for a month 
followed by a slow taper over the second month.13,14
indication: inclusion and exclusion criteria
For inclusion criteria, indications differ slightly in Europe 
and in the USA.
Europe indication: XEN gel stent is intended to reduce 
IOP in patients with primary open-angle glaucoma (OAG) 
who have failed previous medical treatments.
Figure 2 (A) MMC subconjunctival injection; (B) massage; (C) hydroexpansion.
Abbreviation: MMC, mitomycin C.
Figure 3 Sequence of XeN45 gel stent implant (A–D).
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US indication: Management of refractory glaucomas, 
including cases where previous surgical treatment has failed, 
cases of primary OAG, and pseudoexfoliative or pigmen-
tary glaucomas with open angle that are unresponsive to 
maximum-tolerated medical therapy.
The XEN gel stent is generally contraindicated under 
the following circumstances or conditions: angle-closure 
glaucoma (gonioscopically, irido-corneal angle should be 
Shaffer 3 or 4 as narrow angles may cause blockage of the 
AC portion of the XEN implant by the iris; patients with 
Shaffer 2 or less could be selected provided the lens extrac-
tion effectively opened the irido-corneal angle and widened 
the AC); previous glaucoma shunt/valve in the target quad-
rant; presence of conjunctival scarring, prior conjunctival 
surgery or other conjunctival pathologies (eg, pterygium) 
in the target quadrant; active inflammation (eg, blepharitis, 
conjunctivitis, keratitis, and uveitis); active iris neovascular-
ization or neovascularization of the iris within 6 months of 
the surgical date; AC IOL; presence of intraocular silicone 
oil; vitreous present in the AC; impaired episcleral venous 
drainage (eg, Sturge–Weber or nanophthalmos or other 
evidence of elevated venous pressure); known or suspected 
allergy or sensitivity to drugs required for the surgical 
procedure or any of the device components (eg, porcine 
products or glutaraldehyde); and history of dermatologic 
keloid formation.
Clinical data results
Several preclinical studies have been performed using 
animal models (rabbit and canine) and demonstrated that the 
glutaraldehyde cross-linked porcine gelatin did not induce 
significant intraocular inflammation and tissue reaction, not 
undergoing structural change or degradation after 1 year.10
Lewis described a case study in which an implant 
misplaced during early-stage pilot surgery was explanted 
6 months postoperatively and analyzed. No tissue growth on 
the outside or inside was observed, and no signs of fibrosis 
around the implant was reported.4
All published clinical results and complications are briefly 
reported in Tables 1 and 2, respectively.
In the first clinical human study, the implantation of 
2 models of XEN gel stent (XEN140 and XEN63) was 
performed in 37 eyes (though it is not specified how many 
XEN140 and XEN63 have been implanted) with OAG at the 
time of cataract surgery without intraoperative use of MMC. 
Twelve months postoperatively, the mean IOP was signifi-
cantly reduced to 15.4±3.0 mmHg from 22.4±4.2 mmHg pre-
operatively (32.25% mean IOP reduction), with a statistically 
significant reduction of medication classes (from 2.5±1.4 to 
0.9±1.0; 50% of patients completely off medication). Despite 
this study not being designed to address safety, the authors 
reported no major or vision-threatening complications; the 
postoperative needling rate (with MMC or 5-fluorouracil) 
was 32%, although the same authors suspected that this rate 
would be lower if the procedure was performed with MMC 
at the time of implantation.13
Figure 4 Correct implantation of XeN45 gel stent (2.0 mm of exposed implant in 
the subconjunctival space, 1.0 mm in the anterior chamber, and 3.0 mm tunneled 
through sclera).
Table 1 Outcomes of published studies at 12-month follow-up
Author, year Study 
design
XEN 
model ± MMC
Eye 
number
Previous 
glaucoma 
surgery, %
% IOP 
reduction
Patients off 
medications 
after XEN, %
% medication 
classes 
reduction
Needling 
rate, %
Sheybani et al,13 2015 Prospective XeN140 and XeN63 37 None 32.25 50 64 32
Sheybani et al,14 2016 Prospective XeN140 49 45 36.4 42 56.6 43
Pérez-Torregrosa et al,15 2016 Prospective XeN45 + MMC 30 None 29.34 90 94.57 None
De Gregorio et al,12 2017 Prospective XeN45 + MMC 41 2.4 41.82 80.4 84 2.4
Schlenker et al,16 2017 Retrospective XeN45 + MMC 185 None 45.83 74.9 Not specified 43.2
Grover et al,17 2017 Prospective XeN45 + MMCa 65 84.6 35.6 38.5 51.42 32.3
Galal et al,18 2017 Prospective XeN45 + MMC 13 None 29.4 42 94.57 30.7
Notes: MMC: pretreatment with MMC injected in the subconjunctival space. aMMC pretreatment with sponges after conjunctival incision. 
Abbreviations: iOP, intraocular pressure; MMC, mitomycin C.
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Sheybani et al14 published further results of a multicenter, 
nonrandomized and prospective cohort trial on the XEN140 
stand-alone surgical implantation without intraoperative 
MMC use in 49 eyes with refractory OAG. It is interest-
ing to note that 71% (35 of 49 eyes) of the implanted eyes 
had prior failed glaucoma procedures/surgeries: 21 eyes 
had prior trabeculectomy with MMC, 2 eyes had prior 
tube shunt surgery, 3 eyes had prior external trans-scleral 
cyclophotocoagulation, and 9 eyes had laser trabeculoplasty. 
Only 45 eyes completed 12 months of follow-up (3 patients 
required additional glaucoma surgeries), with a mean IOP 
reduction of 36.4% from baseline and a decrease in number of 
medications from 3.0 to 1.3 (42% of patients off medications 
completely). No serious adverse events were reported in this 
study, although 9% of patients needed AC fills with OVD 
in the first postoperative week. None of the patients devel-
oped choroidal detachment, chronic hypotony, or hypotony 
maculopathy during the study period. Approximately 43% 
of patients underwent needling, a higher rate compared with 
current trabeculectomy studies. However, considering that 
more than 50% of patients had previous failed glaucoma 
surgery with conjunctival tissue disruption, the success of 
the device would have been higher and/or the needling rate 
lower if the eyes have had a conjunctival sparing surgery and 
if MMC had been used at the time of implantation.
Pérez-Torregrosa et al15 and De Gregorio et al12 published 
the first 2 clinical prospective studies on XEN45 gel stent 
implantation with adjunctive MMC combined with cataract 
surgery.
The first study was performed on 30 eyes with a diagnosis 
of mild/moderate OAG and cataract, demonstrating an IOP 
reduction of 29.34% at 12 months with a 94.57% medication 
decrease (from 3.07±0.69 to 0.17±0.65). Both intra- and post-
operative complications were relatively minor, often inherent 
to the surgical maneuvers and spontaneously solved.
Indeed, a critical point reported by the authors is the cor-
rect final placement of the stent, emphasizing that the best 
pathway would be 2 mm subconjunctival to avoid extrusion, 
3 mm intra-scleral to increase resistance to reduce exces-
sive drainage, and 1 mm in the AC to limit contact with the 
corneal endothelium. This induced the authors to relocate 6 
implants intraoperatively and reimplant in 1 case. During 
the follow-up, no needling was performed and the authors 
reported only 1 case of fibrosis with encapsulated bleb after 
5 months, treated only with hypotensive medications.15
In the second study published by De Gregorio et al,12 
XEN45 was implanted in 41 eyes with OAG in combination 
with microincisional cataract surgery. Outcomes of this study 
are that XEN45 implant is statistically effective in reducing 
IOP and medications even after 12 months, with an IOP 
reduction of 41.82%, and 80.4% of patients off medication. 
Only 1 patient had previous incisional glaucoma surgery 
(deep sclerectomy). Fifteen (36.6%) patients had allergies 
to anti-hypertensive drugs. All cataract surgeries were 
uneventful and no major complications during implantation 
surgery were experienced except for transient bleedings 
(subconjunctival and/or in the AC).
It is interesting to note that postoperatively, no patients 
needed AC refilling with OVD presumably due to the smaller 
inner diameter of the stent compared with those implanted 
in the first studies. All patients completed 12 months of 
follow-up, excluding 1 patient who needed a trabeculectomy 
after 1 month for a stent failure due to a presumed obstruc-
tion; in 1 case, the implant migrated completely in the AC 
(Figure 5). The implant was explanted and replaced with a new 
one. This study reported only 1 case of bleb fibrosis requiring 
needling (2.4%). The use of subconjunctival MMC in pres-
ence of surgical untouched conjunctival tissue can explain the 
different needling rate respect to the first pilot studies.
An international multicenter retrospective study has 
recently been published that compares the efficacy, safety, 
and risk factors for failure of standalone XEN45 gel stent 
implantation versus trabeculectomy, both with adjunctive 
MMC.16
In this study, 354 eyes with uncontrolled glaucoma and 
no prior incisional filtering surgery underwent microstent 
implantation (n=185) or trabeculectomy (n=169) in 4 aca-
demic ophthalmology centres, providing a large database. 
The results demonstrated that there was no difference in 
efficacy, risk of failure, and safety profile between the 2 sur-
gical procedures.
The most impressive risk factors for failure was the 
presence of diabetes in both kind of interventions. Nonwhite 
Figure 5 XeN45 gel stent dislocation in the anterior chamber.
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patients had statistically significant higher failure rates for 
trabeculectomy but it was not significant for eyes receiving 
microstent. Other statistically significant differential interac-
tions between microstent and trabeculectomy were observed 
regarding preoperative visual acuity and IOP. Eyes with 
preoperative vision better than 0.4 logMAR showed statisti-
cally significantly better results with microstents, whereas 
those with worse vision tended to do better with trabeculec-
tomies; eyes with preoperative IOP of 21 mmHg tended to 
do better with microstents, whereas those with 21 mmHg 
tended to do better with trabeculectomies. One-quarter of 
the microstent eyes and one-third of the trabeculectomy eyes 
were receiving glaucoma medications at the last follow-up; 
more subjects in the trabeculectomy group had post-surgical 
intervention, mostly by laser suture lysis (49.7%), although 
there were likely more needlings (43.2%) in the microstent 
group. The trabeculectomy group had more transient compli-
cations, mostly driven by leaks or dehiscences, though there 
were no cases of long-term complications from hypotony in 
either group.
Despite the large sample size, the multicenter design, and 
the long follow-up (30 months) allowing for reasonable exter-
nal generalizability, the authors emphasized that there were 
several limitations to the study. It was a retrospective study 
and had loss to follow-up, which could over- or underestimate 
the success rate; in addition, it was still underpowered for 
safety considerations.
The multicenter prospective study published by Grover 
et al reported the results at 12 months on performance/safety 
of XEN45 implant following MMC pretreatment in 65 eyes 
with refractory glaucoma (failed prior filtering/cilioablative 
procedure or uncontrolled IOP on maximum-tolerated 
medical therapy).17
In an analysis that excluded patients with missing data 
(n=4) and those who required a glaucoma-related secondary 
surgical intervention (n=9), mean IOP change from baseline 
was 27% at all postoperative visits, reaching −9.1 mmHg 
(35.6% IOP reduction) at 12 months. Compared with base-
line, 36 (69.2%) patients required fewer topical medications, 
16 (30.8%) required the same number, and no patients 
required more (or oral medications). Overall, mean medica-
tion use decreased from 3.5 at baseline (n=65) to 1.7 at 12 
months; in the subgroup analysis specified previously (n=52), 
38.5% of patients did not require any medications.
Intraoperative complications and postoperative adverse 
events reported were mostly mild/moderate and transient, 
resolving without sequelae, and none were unexpected 
in this population of patients with refractory glaucoma. 
The postoperative complication most commonly reported in 
this study was bleb fibrosis requiring needling.
The surgical technique used in this study differs from 
the previous reported for subconjunctival pretreatment with 
MMC. The target area was treated with sponges saturated 
(0.2 mg/mL) for 2 min, assuming a conjunctival incisional 
approach requiring final conjunctiva closure with suture. That 
is the main reason for the observed needling rate (32.3%) 
according to the authors, who underline that the conjuncti-
val opening required for the application of MMC may have 
induced scar formation. Although surgeons who use the 
gelatin stent in other countries have regularly administered 
MMC as a subconjunctival injection prior to the surgery, 
MMC is not Food and Drug Administration-approved for 
subconjunctival injection in the USA.
In a further prospective interventional study recently 
published by Galal et al18 13 eyes with primary OAG and 
no previous trabeculectomy surgery underwent XEN45 
implantation with subconjunctival 0.01% MMC. Of those 
eyes, 3 were pseudophakic and 10 underwent simultaneous 
phacoemulsification and XEN implantation. At the end of 
the follow-up (12 months), patients achieved a mean IOP 
reduction of 29.4% (from 16±4 mmHg pre-op to 12±3 mmHg, 
p=0.01) with a decrease in medication number of 94.57% 
(from 1.9±1 preoperatively to 0.3±0.49, p=0.003); 42% of 
eyes achieved complete success (IOP reduction 20% with-
out any glaucoma medications) and 66% qualified success 
(IOP reduction of 20% with medications). Complications 
included 2 transient hypotony with choroidal detachment that 
was resolved with medical therapy, 1 implant extrusion that 
required repositioning and conjunctival sutures, and 2 eyes 
needed further surgical intervention (trabeculectomy) due to 
inadequately controlled IOP. The rate of needling reported 
in this study was of 30.7%.
It is interesting to highlight that, in all previously men-
tioned studies, baseline mean IOP reported was always on 
therapy and no washout was performed before surgery. 
Consequently, the IOP reduction was calculated comparing 
IOP on therapy before, and IOP mostly off medication after, 
surgery.
Although postoperative adverse events reported in all 
these studies were mostly mild/moderate and transient, it 
is important to mention a case of suprachoroidal bleeding 
2 days after XEN45 implantation reported by Prokosch-
Willing et al.19
In this case report, an 84-year-old female patient with 
pseudoexfoliation glaucoma was correctly implanted with 
XEN45 without complications. On the first postoperative 
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day, the patient presented an IOP of 4 mmHg without 
choroidal detachment, a functioning bleb, and a deep AC. 
On the second postoperative day, she experienced a sudden 
strong pain and developed suprachoroidal bleeding with an 
increased IOP (54 mmHg). A wait-and-see strategy was fol-
lowed and the bleeding resolved spontaneously with medical 
therapy after 6 weeks.
XeN45 “bleb” characteristics and 
management
The presence of subconjunctival fluid upon implantation 
confirms the connection between the AC and subconjunctival 
space. An initial medium or high bleb appearance could be 
present during the immediate postoperative stages. During 
the first week, this bleb gradually reduces in volume, and in 
later stages, the morphology of an established and function-
ing bleb differs from the blebs seen after traditional filtering 
surgeries, being lower lying (Figure 6) due to the diffuse dis-
persion of AH over wide areas in the non-dissected Tenon’s 
and subconjunctival space.7
In the early postoperative period, if the subconjunctival 
AH filtration finds an obstacle to its diffusion (in particular, 
the lower lid margin), a wide-pooling bleb can be pro-
duced. As reported by some authors,20 this hypertrophic 
bleb should be managed to avoid a mechanical ectropion. 
The same authors described the “Dry Lake” technique 
to drain the bleb through a conjunctival incision, treated 
afterward with fibrin tissue adhesive to stick planes. In our 
experience (data not published), a simple needling is 
generally sufficient to remove the subconjunctival fibrotic 
border in the lower margin of the bleb rehabilitating the 
diffuse AH dispersion over all the subconjunctival space 
(Figure 7).
One of the keys to successful filtering surgery is the 
development of a bleb in the postoperative period. Morpho-
logic changes to the developing filtering bleb after surgery 
may help to predict early treatment failure, and guide bleb 
revision and management. An early study by Addicks 
et al21 demonstrated that failed trabeculectomy blebs had 
dense collagenous connective tissue in their walls, while in 
functioning blebs, the subepithelial connective tissue was 
loosely arranged and contained histologically clear spaces. 
Fea et al22 provided a macro- and microscopic analyses of 
bleb morphology in a prospective 12-month study on 12 eyes 
with primary OAG implanted with XEN45 gel stent either 
alone or combined with a cataract surgery. Biomicroscopy, 
in vivo confocal microscopy (IVCM) and anterior segment-
optical coherence tomography (AS-OCT) were used to assess 
bleb morphology.
In this study, AS-OCT showed that bleb wall reflectivity 
was significantly higher in the failure group; IVCM revealed 
that stromal density was significantly lower in the success 
group. Microcysts within the bleb wall epithelium, first 
detected by Labbè et al23 following successful trabeculec-
tomy, were significantly increased in density and area at the 
6-month follow-up visit, suggesting a progressive aqueous 
percolation after stent implantation (Figure 8). Additionally, 
at 6 months, stromal reflectivity was significantly lower in the 
whole superior bulbar conjunctiva compared with previous 
observations, suggesting a slower manifestation of tissue 
Figure 6 Lower-lying filtering bleb in XEN45 gel implant at 6 months.
Figure 7 (A) Hypertrophic XeN45 bleb; (B) after inferior bleb needling.
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rearrangement in deeper layers. On comparing successful 
and failed blebs at 12 months, the stromal density was 
significantly lower in the success group. Increased micro-
cysts and loosely arranged connective tissue/low stromal 
reflectivity are suggestive of new or increased alternative 
AH outflow induced by the stent implantation.
Although the manufacturer has provided some postop-
erative guidance, there is generally limited experience with 
regard to the assessment and postoperative management of 
a “XEN45 bleb”. Simply applying our usual bleb manage-
ment in trabeculectomy may not be suitable for the XEN45 
implant. Further studies should establish whether a less 
aggressive postoperative bleb management approach, in order 
to respect the concept of minimally invasive conjunctival 
sparing surgery, produces similar or better results.
Conclusion
XEN gel stent is an effective MIGS for controlling IOP in 
early, moderate, advanced, or refractory glaucoma patients. 
This surgical approach bypasses all trabecular and scleral 
resistance to create outflow but, unlike other scleral full-
thickness procedures, obviates conjunctival dissection 
and provides sufficient resistance flow through the tube to 
avoid flat chambers or clinically significant hypotony. This 
conjunctiva-sparing ab interno approach with a safe profile 
gives the ophthalmologists a new tool to reach the target IOP 
in refractory glaucoma, as a final step, and in patients intoler-
ant to medical therapy, as an early surgical treatment.
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Figure 8 (A and B) AS-OCT analysis of XeN45 bleb at 6 months.
Abbreviation: AS-OCT, anterior segment-optical coherence tomography.
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